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Abstract
OBJECTIVES—This multi-center pragmatic investigation assessed outcomes following clinical 
implementation of CYP2C19 genotype-guided antiplatelet therapy after PCI.
BACKGROUND—CYP2C19 loss-of-function alleles impair clopidogrel effectiveness after 
percutaneous coronary intervention (PCI).
METHODS—After clinical genotyping, each institution recommended alternative antiplatelet 
therapy (prasugrel, ticagrelor) in PCI patients with a loss-of-function allele. Major adverse 
cardiovascular events (MACE, defined as myocardial infarction, stroke, or death) within 12 
months of PCI were compared between patients with a loss-of-function allele prescribed 
clopidogrel versus alternative therapy. Risk was also compared between patients without a loss-of-
function allele and loss-of-function allele carriers prescribed alternative therapy. Cox regression 
was performed, adjusting for group differences with inverse probability of treatment weights.
RESULTS—Among 1,815 patients, 572 (31.5%) had a loss-of-function allele. The risk for 
MACE was significantly higher in patients with a loss-of-function allele prescribed clopidogrel 
versus alternative therapy [23.4 vs. 8.7 per 100 patient-years; adjusted hazard ratio (HR): 2.26; 
95% confidence interval (CI): 1.18 to 4.32; p=0.013]. Similar results were observed among 1,210 
patients with an acute coronary syndrome at the time of PCI (adjusted HR: 2.87; 95% CI: 1.35 to 
6.09, p=0.013). There was no difference in MACE between patients without a loss-of-function 
allele and loss-of-function allele carriers prescribed alternative therapy (adjusted HR: 1.14, 95% 
CI: 0.69 to 1.88, p=0.60).
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CONCLUSIONS—These data from real-world observations demonstrate a higher risk for 
cardiovascular events in patients with a CYP2C19 loss-of-function allele if clopidogrel versus 
alternative therapy is prescribed. A future randomized study of genotype-guided antiplatelet 
therapy may be of value.
Keywords
clopidogrel; CYP2C19; pharmacogenomics; percutaneous coronary intervention; cardiovascular 
events; anti-platelet therapy
INTRODUCTION
Treatment with a P2Y12 inhibitor plus aspirin is the standard of care following percutaneous 
coronary intervention (PCI) (1,2). The P2Y12 inhibitor clopidogrel is a prodrug requiring 
bioactivation by cytochrome P450 (CYP) 2C19. CYP2C19 loss-of-function (LOF) alleles 
lead to reduced or absent CYP2C19 activity, lower plasma concentrations of the clopidogrel 
active metabolite and reduced inhibition of platelet aggregation during clopidogrel therapy 
(3,4). Retrospective analyses from randomized clinical trials and patient registries have 
demonstrated a higher risk for major adverse cardiovascular events (MACE) in clopidogrel-
treated patients with versus without a CYP2C19 LOF allele, particularly after PCI (3,5–7).
Prasugrel and ticagrelor are alternative P2Y12 inhibitors, shown to be superior to clopidogrel 
in preventing MACE in patients with an acute coronary syndrome (ACS) in the TRITON-
TIMI 38 and PLATO trials, respectively (8,9). Post hoc genetic analyses from these trials 
showed no effect of CYP2C19 genotype on outcomes with either prasugrel or ticagrelor 
(7,10). However, both drugs are more expensive than clopidogrel, which is available 
generically, and are associated with an increased bleeding risk. Ticagrelor is also associated 
with more frequent discontinuation due to side effects compared to clopidogrel (8).
While several institutions have implemented clinical CYP2C19 genotyping to guide 
antiplatelet therapy selection after PCI (11–14), the impact of this strategy on clinical 
outcomes is not well defined. Therefore, among patients who underwent a PCI and clinical 
CYP2C19 genotyping, we compared the risk for MACE between patients with a CYP2C19 
LOF allele prescribed clopidogrel 75 mg/day and those with a CYP2C19 LOF allele 
prescribed alternative antiplatelet therapy. We also compared MACE risk between those with 
a LOF allele prescribed alternative therapy and those without a CYP2C19 LOF allele treated 
with any P2Y12 inhibitor.
METHODS
STUDY DESIGN
This was a multi-center investigation of clinical CYP2C19 genotype-guided antiplatelet 
therapy post-PCI. The study design was pragmatic based on delivery of the genotype 
intervention as part of clinical care, the ultimate decision to order genetic testing and choice 
of drug therapy left to the discretion of the physician, unobtrusive collection of data from the 
electronic health record (EHR), and the focus on an objectively measured and clinically 
meaningful outcome (15–17). Seven institutions (University of Florida; University of North 
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Carolina, Chapel Hill; University of Maryland, Baltimore; University of Alabama, 
Birmingham; University of Illinois, Chicago; University of Pittsburgh; and Indiana 
University) implemented clinical CYP2C19 genotyping with results returned via the EHR 
for consideration during antiplatelet therapy prescribing. All sites participated in the NIH-
funded Implementing Genomics in Practice (IGNITE) Network Pharmacogenetics Working 
Group and contributed data (18). All patients from each site ≥18 years of age who 
underwent PCI and CYP2C19 genotyping (per the strategy described in ONLINE TABLE 1) 
and received a P2Y12 inhibitor after PCI were included, regardless of length of follow-up. A 
total of 1,815 patients across the seven institutions met these criteria and were included in 
the analysis.
CYP2C19 GENOTYPING AND PHENOTYPING
Genotyping was performed at each institution in a Clinical Laboratory Improvement 
Amendments (CLIA)-licensed laboratory, with the test ordered prior to or at the time of PCI. 
All sites genotyped for the LOF CYP2C19*2 and *3 alleles, with additional rare alleles 
genotyped at 5 institutions (ONLINE TABLE 1). CYP2C19 LOF allele status was defined 
by presence of at least one LOF allele.
CYP2C19 phenotype was assigned similarly across sites based on standardized definitions 
(19). Patients with one or two LOF alleles were assigned the intermediate metabolizer (IM) 
or poor metabolizer (PM) phenotype, respectively. Alternative antiplatelet therapy, 
consisting of prasugrel or ticagrelor in the absence of contraindications, was recommended 
for IMs and PMs, according to Clinical Pharmacogenetics Implementation Consortium 
guidelines (20). Ultimate antiplatelet therapy selection was left to the discretion of the 
prescriber.
DATA ABSTRACTION
Data abstraction procedures were approved by the Institutional Review Board at each 
institution. Clinical data at baseline and for up to 12 months following the index PCI, 
defined as the PCI performed in association with genotyping, were manually abstracted from 
the EHR through review of patient encounters, including the index PCI hospitalization and 
subsequent hospitalizations and outpatient visits, using a common data collection form (18). 
The occurrence of clinical outcomes of interest, including death, myocardial infarction (ST-
segment or non-ST-segment elevation myocardial infarction), ischemic stroke, stent 
thrombosis, and unstable angina occurring over the 12-month period after the index PCI was 
determined. The date range for data abstraction was June 2012 through April 2016.
PRIMARY AND SECONDARY OUTCOMES
The primary outcome was the composite of MACE, defined as first occurrence of 
myocardial infarction, ischemic stroke, or death within 12 months following the index PCI 
(5). Secondary outcomes were the composite of MACE plus stent thrombosis and unstable 
angina and individual components of MACE. Outcomes were identified based on physician-
reported diagnoses abstracted from the cardiac catheterization laboratory report, hospital 
discharge summary notes, or clinical notes in the event of death. Antiplatelet therapy was 
assessed at the time of event or last follow-up in which P2Y12 inhibitor treatment was 
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documented. The number of days between the index PCI and initiation of alternative 
antiplatelet therapy was determined in patients with a LOF allele and was available for all 
but four patients.
STATISTICAL ANALYSIS
Data were curated and aggregated at the University of Florida. The time of index PCI was 
considered time zero. Patients who did not experience MACE during the 12 months post-
PCI were censored at the time of the last EHR-documented follow-up in which treatment 
with a P2Y12 inhibitor was documented. Event rates were calculated as number of events 
divided by follow-up time (time-to-event or censoring) and expressed as events per 100 
patient-years.
Patient characteristics and PCI features at the time of the index PCI were compared between 
patients with a LOF allele prescribed either clopidogrel 75 mg/day (LOF-clopidogrel group) 
or alternative antiplatelet therapy (LOF-alternative group) by the Student’s unpaired t-test, 
Chi-square analysis, or Fisher’s exact test as appropriate. Additional comparisons were 
made between non-LOF patients prescribed clopidogrel or alternative antiplatelet therapy 
(non-LOF group) and LOF-alternative patients and between clopidogrel-treated versus 
alternatively treated-patients in the non-LOF group. All patients were included in the MACE 
outcome analyses. A pre-specified secondary analysis limited to patients with an ACS 
indication (ST-segment elevation or non-ST-segment elevation myocardial infarction or 
unstable angina) at the index PCI was also conducted.
Kaplan Meier plots were generated to estimate the cumulative risk of an event comparing 
patients in the LOF-clopidogrel versus LOF-alternative groups, and also patients in the non-
LOF versus LOF-alternative groups. To adjust for differences between groups, we used 
logistic regression to estimate the probability (propensity score) of receiving clopidogrel 
versus alternative antiplatelet therapy using previously reported risk factors for 
cardiovascular events, and study site (2). Propensity scores were estimated separately for 
each comparison. Stabilized inverse probability of treatment weights (IPTW) were 
calculated using the estimated propensity score (21). Covariate balance between groups was 
assessed by examining the magnitude of any residual differences between groups after 
applying the weights. Differences were quantified as the weighted standardized differences, 
where a threshold of 10% was used to signify a meaningful difference in covariates (21). We 
also examined the weights themselves to ensure that no observations were overly influential. 
To compare risk for primary and secondary outcomes, we constructed cause-specific Cox 
proportional hazard models, weighted by IPTW. As a sensitivity analysis, we also estimated 
cluster robust standard errors by accounting for clustering by study site. All statistical 
analyses were performed in SAS (version 9.4, SAS Institute, Cary, North Carolina).
A total sample size of 1,815 patients, with at least 30% having an LOF allele and 60% of 
LOF allele carriers receiving alternative therapy, provided over 90% power with an alpha 
level of 0.05 to detect a hazard ratio of 2.0 for MACE between the LOF-clopidogrel and 
LOF-alternative groups.
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RESULTS
PATIENT CHARACTERISTICS
Patient characteristics are summarized in Table 1. Among 1,815 patients, 1,210 (66.7%) 
presented with an ACS, and 1,793 (98.8%) had a stent placed at the time of PCI. The 
majority of patients received a drug eluting stent (83.6%), and were prescribed aspirin 
(98.2%) in addition to a P2Y12 inhibitor.
Genotypes and associated phenotypes are shown in Online Table 2. The median time from 
index PCI to available genotype result was one day (interquartile range, IQR, one to three 
days). A LOF allele was present in 572 patients (31.5%; Figure 1, Online Table 2); 518 
patients (28.5%) were IMs, and 54 patients (3%) were PMs. Alternative antiplatelet therapy 
was prescribed to a higher proportion of patients with a LOF allele (60.5%) compared to 
patients without a LOF allele (15.5%, p<0.0001, Figure 1). Fifty-eight percent of IMs and 
87% of PMs were prescribed alternative antiplatelet therapy (Online Figure 1). Among 
patients with a LOF allele, the median time from genotype result to initiation of alternative 
antiplatelet therapy was one day (IQR: one to six days).
There were differences between the LOF-clopidogrel and LOF-alternative groups in age, 
prevalence of diabetes, stroke, peripheral vascular disease, and use of oral anticoagulation 
(Table 1). Age and prevalence of hypertension and diabetes differed between the non-LOF 
and LOF-alternative groups. These imbalances were negligible after adjustment with 
propensity score-derived IPTW (Table 2).
CLINICAL OUTCOMES
The median follow-up from index PCI to MACE or censoring was 4.8 months (IQR: 0.6 to 
9.9 months). MACE was documented in 108 patients (5.95%) over the follow-up period 
(event rate of 13.5 per 100 patient-years). There was a higher rate of MACE in the LOF-
clopidogrel group (n=18 events; event rate of 23.4 per 100 patient-years) compared to the 
LOF-alternative group (n=16 events; 8.7 per 100 patient-years; log rank p=0.016, Table 3, 
Figure 2). After propensity score adjustment, risk for MACE remained significantly higher 
in the LOF-clopidogrel versus LOF-alternative group (adjusted HR: 2.26; 95% CI: 1.18 to 
4.32, p=0.013, Table 3). There was no difference in event rates between the non-LOF and 
LOF-alternative groups (13.7 versus 8.7 per 100 patient-years; log rank p=0.15; propensity 
score adjusted HR: 1.14; 95% CI: 0.69 to 1.88, p=0.60, Table 3). Similarly, within the non-
LOF group, there was no difference in MACE rates between non-LOF patients treated with 
clopidogrel versus non-LOF patients treated with alternative therapy after adjusting for 
clinical differences between groups (adjusted HR: 1.01; 95% CI: 0.52 to 1.94, p=0.98, 
Online Tables 3 and 4). Accounting for within site clustering did not change the estimates 
for the primary outcome (Online Table 5).
In the 518 patients with the IM phenotype only, the risk for MACE was significantly higher 
with clopidogrel versus alternative antiplatelet therapy (log rank p=0.003, Online Figure 2), 
with event rates of 24.0 versus 6.7 per 100 patient-years, respectively. Only 7 of 54 PMs 
(13%) were treated with clopidogrel, precluding analysis of outcomes in this group.
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Secondary outcomes are shown in Table 3. The risk for MACE plus other ischemic events 
(stent thrombosis and unstable angina) was higher in the LOF-clopidogrel versus LOF-
alternative group (adjusted HR: 1.82; 95% CI: 1.07 to 3.12, p=0.027). There was no 
difference in MACE plus ischemic events between non-LOF and LOF-alternative groups 
(adjusted HR: 1.09; 95% CI: 0.72 to 1.63, p=0.69, Table 3) or between non-LOF patients 
treated with clopidogrel versus alternative therapy (adjusted HR: 1.02; 95% CI: 0.59 to 1.78, 
Online Table 3). Patients presenting with ACS at the time of index PCI (1,210 of 1,815 
patients) contributed the majority of events to the analysis, including 86 of 108 (80%) 
MACE and 48 of 58 (83%) myocardial infarctions. Consistent with the analysis of the 
overall study population, among patients with ACS, the LOF-clopidogrel group had a higher 
rate of MACE compared to the LOF-alternative group (39.0 versus 8.9 per 100 patient-years, 
respectively; adjusted HR: 2.87; 95% CI: 1.35 to 6.09, p=0.013, Online Figure 3, Online 
Table 6). The risk of MACE plus other ischemic events (adjusted HR: 2.10; 95% CI: 1.12 to 
3.90, p=0.019) was also significantly elevated. No differences in outcomes were observed 
between non-LOF and LOF-alternative groups in the ACS subset. Though not an outcome of 
the study, moderate and severe/life-threatening bleeding events, defined according to the 
GUSTO (Global Utilization of t-PA and Streptokinase for Occluded Coronary Arteries) 
criteria, were observed in 2.3% of patients in the overall study population and were similar 
across groups (22).
Based on the prevalence of patients with a LOF allele (31.5%), the number needed to 
genotype to identify a LOF allele carrier for whom alternative therapy would be 
recommended is 3.2. With an absolute difference in the proportion of patients who had a 
MACE in the LOF-clopidogrel (8.0%) and LOF-alternative (4.6%) groups (Table 3), the 
number of patients with a LOF allele needed to treat with alternative antiplatelet therapy to 
prevent one event is 29 (1/0.034). Therefore, the number of patients needed to genotype, 
with alternative antiplatelet therapy prescribed for all patients with a LOF allele, to prevent 
one cardiovascular event is 93 (29 times 3.2).
DISCUSSION
Our study is the first large multi-center study to examine outcomes after clinical 
implementation of CYP2C19 genotype-guided antiplatelet therapy. We demonstrate the 
feasibility of genotype-guided antiplatelet therapy after PCI across multiple institutions, with 
efficient return of genotype results and high uptake of alternative antiplatelet therapy in 
patients with a LOF allele. More importantly, our results show a higher risk for MACE in 
patients with a CYP2C19 LOF allele who are treated with clopidogrel versus alternative 
antiplatelet therapy. Most events occurred in patients with an ACS indication at the index 
PCI, in whom the risk for MACE was higher in LOF-clopidogrel versus LOF-alternative 
patients.
Retrospective genetic substudies of large clinical trials suggested worse outcomes in patients 
with a CYP2C19 LOF allele treated with clopidogrel (3,5–7), but there is a paucity of data 
from large prospective clinical trials on outcomes with CYP2C19 genotype-guided 
antiplatelet therapy. This has hindered inclusion of CYP2C19 genotyping in clinical practice 
and PCI practice guidelines. Guidelines state that routine genetic testing is not 
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recommended, but might be considered in high-risk patients (Class IIb, Level of Evidence 
C) (1,2). A randomized controlled trial assessing the efficacy of genotype-guided antiplatelet 
therapy in a target population of over 5,000 patients began in 2013, but is not expected to be 
completed until 2020 (ClinicalTrials.gov Identifier NCT01742117). Given the magnitude, 
time, and expense of conducting traditional randomized controlled trials, other approaches 
are needed to generate an evidence base quantifying clinical outcomes related to 
pharmacogenetic-tailored therapy. Our pragmatic approach to assessing outcomes following 
clinical implementation of CYP2C19 genotyping with real-world evidence is one such 
approach.
Our findings are in line with recent data from the Netherlands and Spain (23,24). The 
Netherlands study focused on patients undergoing elective PCI, who were clinically 
genotyped, with prasugrel recommended for PMs (23). Fewer adverse cardiovascular events 
were observed in PMs treated with prasugrel versus clopidogrel. The Spanish study included 
patients undergoing elective or emergent PCI, and recommendations for alternative therapy 
were made for both PMs and IMs (24). Compared to historic controls without genotyping, 
fewer adverse events were observed in patients receiving genotype-guided therapy. Our data 
are also consistent with those from two trials of Chinese patients undergoing PCI and 
randomized to either clopidogrel 75 mg/day or genotype-guided antiplatelet therapy, 
consisting of high dose clopidogrel (150 mg/day) for IMs and high dose clopidogrel plus 
cilostazol for PMs in one trial and ticagrelor for PMs in the other (25,26). Both studies 
observed a significant reduction in MACE in the genotype-guided arm.
The FDA-approved clopidogrel label warns of reduced clopidogrel effectiveness in PMs, and 
recommends consideration of alternative antiplatelet therapy in these patients, but is silent 
regarding risk and recommendations in IMs (27). In our study conducted in the context of 
routine clinical care, the majority of PMs (87%) were treated with alternative antiplatelet 
therapy, consistent with labeling recommendations, but a lower proportion of IMs were 
treated with alternative antiplatelet therapy (58%). This observation suggests that an IM test 
result is weighed less heavily than a PM result in the post-PCI antiplatelet therapy 
prescribing decision. However, when limiting our analysis to IMs, we observed a 
significantly higher rate of MACE with clopidogrel versus alternative antiplatelet therapy. 
These data indicate that IMs, like PMs, are at higher risk of adverse cardiovascular outcomes 
if treated with clopidogrel, and suggest that alternative antiplatelet therapy should be 
considered in both IMs and PMs.
Our real-world data corroborate those from retrospective analyses of clinical trials showing a 
higher risk for MACE among clopidogrel-treated patients with versus without a LOF allele 
(3,5–7). In the absence of a LOF allele, data from the TRITON-TIMI 38 trial also suggest 
that the risk for MACE may be comparable between clopidogrel and prasugrel, with a 
genetic substudy of the trial showing a relative risk for MACE of 0.98 (95% CI, 0.80–1.20) 
with prasugrel compared to clopidogrel in patients without a LOF allele. (28) The 
association between genotype and outcomes with clopidogrel appears to be indication 
specific, with strong and consistent associations in patients undergoing PCI, but not among 
lower-risk patients, such as those with atrial fibrillation or ACS managed medically 
(5,7,29,30). This is most clearly demonstrated in a meta-analysis showing an association 
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between CYP2C19 LOF genotype and risk for MACE when analyzing studies of 
clopidogrel-treated patients undergoing PCI, but not when analyzing those without PCI (6).
Across institutions in our study, clopidogrel was the most commonly prescribed P2Y12 
inhibitor among patients without a CYP2C19 LOF allele. This is consistent with other data 
suggesting that clopidogrel remains the predominant antiplatelet therapy in the U.S., 
prescribed 60% to 70% of the time according to published data through the first half of 2013 
(31,32). To provide more contemporary use data, we interrogated practice patterns at 
Vanderbilt University Medical Center in the Southeastern U.S., and Sanford Medical Center, 
which draws patients from 6 states in the Midwestern U.S. Current practice patterns in these 
geographic locales demonstrate that clopidogrel remains commonly prescribed following 
PCI, regardless of clinical context. Specifically, among 10,115 patients who underwent PCI 
(41% with ACS) at Vanderbilt University Medical Center from 2010 to 2015, clopidogrel 
use fell minimally, from 93% to 72%, during that time (unpublished data). Similarly, among 
1,260 patients from Sanford Medical Center who underwent PCI at 15 catheterization 
laboratories during the first 9 months of 2016, 53% with an ACS and 77% without ACS 
were discharged on clopidogrel (unpublished data).
Per PCI guidelines, the use of alternative antiplatelet agents in preference to clopidogrel 
after ACS and PCI is a Class IIa recommendation based on a moderate quality of evidence 
(1). In patients started on alternative P2Y12 inhibitors according to PCI guidelines, 
CYP2C19 genotype may still have an important role in informing therapy, especially after 
the 30-day post-PCI period when risk for events is highest (1). In patients with a high risk 
for bleeding or difficulty affording or tolerating newer agents, knowledge that a patient does 
not carry a LOF allele may give physicians increased confidence when considering 
switching the patient to the more affordable clopidogrel.
We did not directly assess why physicians chose to start some patients with a LOF allele on 
alternative therapy but not others. However, some speculation can be made based on 
prescribing patterns and characteristics of treatment groups. First, the higher use of 
alternative therapy in PMs versus IMs suggests that physicians may heed the boxed warning 
in the clopidogrel labeling and place a stronger emphasis on using alternative therapy in 
PMs, the focus of the boxed warning. Secondly, the higher prevalence of stroke or TIA 
history and concurrent anticoagulant use in the LOF-clopidogrel group versus the LOF-
alternative group suggests that patient bleeding risk influenced preference for antiplatelet 
therapy.
LIMITATIONS
Our study has several limitations. First, there was no control group who did not undergo 
genotyping. However, some comparisons can be made with published event rates. In 
particular, in a genetic sub-study of the TRITON-TIMI 38 trial of patients with ACS and 
PCI, 8% of clopidogrel-treated patients without a LOF allele and 12% with a LOF allele had 
a MACE (3). Rates in our study were comparable, with a MACE occurring in 7% of ACS 
patients without a LOF allele (most of whom received clopidogrel) and 11% of clopidogrel-
treated patients with a LOF allele. Secondly, genotype-guided therapy was not randomized, 
due to our pragmatic design, and antiplatelet therapy selection was left to physician 
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discretion. Thus, propensity scoring methods were used to mitigate the potential 
confounding effects related to differences across groups, and balance was achieved across 
comparison groups after weighting with IPTW. However, residual confounding regarding the 
choice of antiplatelet therapy may remain. Third, because ascertainment of outcomes was 
confined to the EHR without event adjudication, clinical events, including deaths, may have 
been missed. Fourth, length of follow-up was variable, as is typical for the clinical setting. 
As such, event rates were reported. Fifth, bleeding events were not objectively and 
systematically collected, given known difficulties in accurate bleeding assessment and the 
focus of data collection for this analysis on ischemic outcomes (33). Finally, because of the 
limited number of patients who underwent elective PCI, we did not examine outcomes 
separately in this group.
CONCLUSION
We demonstrate that implementation of clinical CYP2C19 genotyping to guide post-PCI 
antiplatelet therapy is feasible across multiple institutions. Our data also demonstrate that 
cardiovascular outcomes were worse when clopidogrel versus alternative antiplatelet therapy 
was prescribed after PCI in patients with a LOF allele. The higher risk for MACE in LOF 
carriers prescribed clopidogrel was also evident when analyses were confined to ACS 
patients and, separately, to IMs (with a single LOF allele). Our data suggest that obtaining 
genotype data early after PCI allows identification of patients with a CYP2C19 LOF allele 
in whom alternative antiplatelet therapy would reduce risk for events. A future randomized 
study of genotype-guided antiplatelet therapy may be of value.
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PERSPECTIVES
WHAT IS KNOWN?
CYP2C19 loss-of-function alleles impair clopidogrel activation and effectiveness after 
percutaneous coronary intervention. However, the impact of genotype-guided antiplatelet 
therapy on clinical outcomes is not well defined.
WHAT IS NEW?
This study demonstrates that patients with one or two CYP2C19 loss-of-function alleles 
prescribed an alternative P2Y12 inhibitor after PCI exhibit lower risk for cardiovascular 
events compared to patients with one or two CYP2C19 loss-of-function alleles prescribed 
clopidogrel.
WHAT IS NEXT?
Strategies to more broadly incorporate genotyping into clinical care to inform antiplatelet 
therapy prescribing decisions after PCI, and to evaluate the impact on health care costs, 
warrant further investigation.
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FIGURE 1. Study Population by CYP2C19 Genotype Group and Antiplatelet Therapy
*Alternative therapy in patients with a LOF allele consisted of prasugrel (n=222), ticagrelor 
(n=116), or high dose clopidogrel (150 mg/day, n=2; 225 mg/day, n=6).
†Alternative therapy in the non-LOF group consisted of prasugrel (n=125) or ticagrelor 
(n=68).
‡p<0.001 for use of alternative therapy in the non-LOF group compared to the LOF group.
APT, antiplatelet therapy; LOF, loss-of-function; PCI, percutaneous coronary intervention
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FIGURE 2, CENTRAL ILLUSTRATION. Outcomes with Clinical Implementation of CYP2C19-
Guided Antiplatelet Therapy after PCI
Data are shown for patients with a CYP2C19 loss-of-function (LOF) allele treated with 
clopidogrel (LOF-Clopidogrel), patients with a LOF allele treated with alternative 
antiplatelet drug therapy (LOF-Alternative), and patients without an LOF allele treated with 
either clopidogrel or alternative therapy (non-LOF). The unadjusted log-rank p-values for 
the LOF-Clopidogrel group compared to LOF-Alternative group and for the Non-LOF group 
compared to the LOF-Alternative group are provided. LOF, loss-of-function; MACE, major 
adverse cardiovascular events
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TABLE 1
Patient Characteristics at the Time of Index PCI
Characteristic All patients (n=1815) LOF- Alternative (n=346) LOF- Clopidogrel (n=226) Non-LOF (n=1243)
Age, years 62.7 ± 11.8 61.4 ± 11.4 64.3 ± 11.7* 62.8 ± 11.8*
Male sex 1224 (67.4) 245 (70.8) 150 (66.4) 829 (66.7)
Race
 White 1416 (78.0) 267 (77.2) 172 (76.1) 977 (78.6)
 Black 285 (15.7) 54 (15.6) 39 (17.3) 192 (15.4)
 Other 114 (6.3) 25 (7.2) 15 (6.6) 74 (6.0)
BMI, kg/m2 30.0 ± 6.2 30.1 ± 7.0 30.0 ± 6.5 29.8 ± 5.9
Current smoker 548 (30.2) 96 (27.7) 80 (35.4) 372 (29.9)
PCI indication
 ACS 1210 (66.7) 237 (68.5) 145 (64.2) 828 (66.6)
  STEMI 350 (19.3) 75 (21.7) 33 (14.6) 242 (19.5)
  Non-STEMI 513 (28.3) 96 (27.7) 72 (31.8) 345 (27.7)
  Unstable angina 347 (19.1) 66 (19.1) 40 (17.7) 241 (19.4)
 Stable coronary disease 553 (30.5) 99 (28.6) 70 (31.0) 384 (30.9)
 Other/unknown 52 (2.8) 10 (2.9) 11 (4.9) 31 (2.5)
Pre-PCI P2Y12 inhibitor†
 Clopidogrel 1204 (66.3) 202 (58.4) 178 (78.8) 824 (66.3)
 Prasugrel 235 (12.9) 68 (19.7) 6 (2.7) 161 (13.0)
 Ticagrelor 218 (12.0) 47 (13.6) 23 (10.2) 148 (11.9)
 Not available 158 (8.7) 29 (8.4) 19 (8.4) 110 (8.8)
PCI type‡
 Drug eluting stent 1518 (83.6) 293 (84.7) 182 (80.5) 1043 (83.9)
 Bare metal stent 275 (15.2) 46 (13.3) 40 (17.7) 189 (15.2)
 Balloon angioplasty 21 (1.2) 7 (2.0) 3 (1.3) 11 (0.9)
Medical history
 Hypertension 1449 (79.8) 260 (75.1) 183 (81.0) 1006 (80.9)*
 Diabetes 691 (38.1) 110 (31.8) 93 (41.2)* 488 (39.3)*
 Dyslipidemia 1229 (67.7) 236 (68.2) 154 (68.1) 839 (67.5)
 Chronic Kidney Disease§ 538 (29.6) 106 (30.6) 77 (34.1) 355 (28.6)
 Myocardial infarction 470 (25.9) 86 (24.9) 68 (30.1) 316 (25.4)
 Revascularization 779 (42.9) 137 (39.6) 103 (45.6) 539 (43.4)
 Coronary artery bypass graft 313 (17.3) 61 (17.7) 43 (19.0) 209 (16.9)
 Heart failure 252 (13.9) 42 (12.1) 37 (16.4) 173 (13.9)
 Left ventricular EF (%)? 51.7 ± 11.9 52.4 ± 11.4 50.2 ± 12.8 51.8 ± 11.9
 Stroke or TIA 183 (10.1) 24 (6.9) 36 (15.9)* 123 (9.9)
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Characteristic All patients (n=1815) LOF- Alternative (n=346) LOF- Clopidogrel (n=226) Non-LOF (n=1243)
 Peripheral vascular disease 155 (8.5) 24 (6.9) 28 (12.4)* 103 (8.3)
 Atrial fibrillation/flutter 159 (8.8) 27 (7.8) 25 (11.1) 107 (8.6)
 Gastrointestinal bleed 54 (3.0) 14 (4.1) 10 (4.4) 30 (2.4)
Discharge medication
 Aspirin 1782 (98.2) 342 (98.8) 220 (97.4) 1220 (98.2)
 Proton pump inhibitor 586 (32.3) 110 (31.8) 72 (31.9) 404 (32.5)
 Anticoagulant 152 (8.4) 22 (6.4) 26 (11.5)* 104 (8.4)
 Statin 1686 (92.9) 329 (95.1) 210 (92.9) 1147 (92.3)
 ACE inhibitor or ARB 1202 (66.2) 238 (68.8) 152 (67.3) 812 (65.3)
 B-blocker 1539 (84.8) 285 (82.4) 181 (80.1) 1073 (86.3)
No. (%) or mean ± SD
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; EF, ejection fraction; PCI, percutaneous 
coronary intervention; STEMI, ST-segment elevation myocardial infarction; TIA, transient ischemic attack
LOF-Clopidogrel patients were those with at least 1 loss-of-function allele (i.e. *2, *3…) treated with clopidogrel
LOF-Alternative patients were those with at least 1 loss-of-function allele (i.e. *2, *3…) treated with prasugrel, ticagrelor, or high dose clopidogrel
Non-LOF patients were those with no loss-of-function allele: *1/*1, *1/*17, or *17/*17 genotype.
*p<0.05 compared to LOF-Alternative group
†
Pre-PCI P2Y12 inhibitor defined as drug used for loading or, if the drug used for loading was not reported, P2Y12 inhibitor on admission was 
used.
‡One patient had a stent placed but no data were provided on type of stent
§Chronic kidney disease defined as an estimated creatinine clearance (based on the Cockcroft-Gault formula) <60 ml/min
?
Left ventricular ejection fraction, as measured during cardiac catheterization, was available for 1,274 patients
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